Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Page 1
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
Philis-Tsimikas A, Bajaj HS, Begtrup K, Cailleteau R, Gowda A, Lingvay I, Mathieu C, Russell-Jones D, Rosenstock J. Philis-Tsimikas A, et al. Among authors: russell jones d. Diabetes Obes Metab. 2023 Feb;25(2):331-341. doi: 10.1111/dom.14871. Epub 2022 Oct 14. Diabetes Obes Metab. 2023. PMID: 36106652 Free PMC article. Clinical Trial.
Each trial will investigate icodec use in a unique clinical scenario, with consideration of long-term safety and varied comparator treatments (insulin glargine U100 or U300 or insulin degludec). ...
Each trial will investigate icodec use in a unique clinical scenario, with consideration of long-term safety and varied comparator tr …
Lessons for modern insulin development.
Herring R, Russell-Jones DDL. Herring R, et al. Among authors: russell jones ddl. Diabet Med. 2018 Oct;35(10):1320-1328. doi: 10.1111/dme.13692. Epub 2018 Jun 15. Diabet Med. 2018. PMID: 29802638 Review.
This may lead to fewer side effects of therapy resulting in a lower risk of hypoglycaemia and less weight gain, which could in turn could reduce long-term complications for people with diabetes....
This may lead to fewer side effects of therapy resulting in a lower risk of hypoglycaemia and less weight gain, which could in turn could re …
Identification of barriers to insulin therapy and approaches to overcoming them.
Russell-Jones D, Pouwer F, Khunti K. Russell-Jones D, et al. Diabetes Obes Metab. 2018 Mar;20(3):488-496. doi: 10.1111/dom.13132. Epub 2017 Nov 22. Diabetes Obes Metab. 2018. PMID: 29053215 Free PMC article. Review.
Tackling clinical or therapeutic inertia, where the person with diabetes and/or their healthcare providers do not intensify treatment regimens despite this being appropriate, is key to improving patients' long-term outcomes. This gap between best practice and current level …
Tackling clinical or therapeutic inertia, where the person with diabetes and/or their healthcare providers do not intensify treatment regime …
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary …
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with t …
Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.
Russell-Jones D, Heller SR, Buchs S, Sandberg A, Valentine WJ, Hunt B. Russell-Jones D, et al. Diabetes Obes Metab. 2017 Dec;19(12):1773-1780. doi: 10.1111/dom.13026. Epub 2017 Jul 25. Diabetes Obes Metab. 2017. PMID: 28573681 Free PMC article. Clinical Trial.
AIM: To assess the impact of faster aspart vs insulin aspart on long-term clinical outcomes and costs for patients with type 1 diabetes mellitus (T1DM) in the UK setting. ...
AIM: To assess the impact of faster aspart vs insulin aspart on long-term clinical outcomes and costs for patients with type 1 diabet …
Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.
Bain SC, Feher M, Russell-Jones D, Khunti K. Bain SC, et al. Among authors: russell jones d. Diabetes Obes Metab. 2016 Dec;18(12):1157-1166. doi: 10.1111/dom.12760. Epub 2016 Sep 14. Diabetes Obes Metab. 2016. PMID: 27491724 Review.
The importance of good glycaemic control in the prevention of microvascular complications of diabetes is widely accepted, and there is a growing body of evidence to support a benefit in the reduction of cardiovascular events in the long term. Despite the importance of main …
The importance of good glycaemic control in the prevention of microvascular complications of diabetes is widely accepted, and there is a gro …
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators. Bode BW, et al. Among authors: russell jones dl. Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17. Diabet Med. 2013. PMID: 23710902 Free PMC article. Clinical Trial.
AIMS: The goal of this study was to compare the long-term safety and efficacy of the basal insulin analogue, insulin degludec with insulin glargine (both with insulin aspart) in Type 1 diabetes, over a 2-year time period. ...Despite achieving similar glycaemic control, ins …
AIMS: The goal of this study was to compare the long-term safety and efficacy of the basal insulin analogue, insulin degludec with in …
Hepatoselectivity and the evolution of insulin.
Herring R, Jones RH, Russell-Jones DL. Herring R, et al. Among authors: russell jones dl. Diabetes Obes Metab. 2014 Jan;16(1):1-8. doi: 10.1111/dom.12117. Epub 2013 May 16. Diabetes Obes Metab. 2014. PMID: 23679086 Review.
In spite of major developments in insulin production, purification, pharmaceutical formulation and methods of delivery, problems remain both in the day to day management of insulin-treated diabetes and with regard to its long-term complications. The risks of hypoglycaemia …
In spite of major developments in insulin production, purification, pharmaceutical formulation and methods of delivery, problems remain both …
Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men.
Robertson MD, Russell-Jones D, Umpleby AM, Dijk DJ. Robertson MD, et al. Among authors: russell jones d. Metabolism. 2013 Feb;62(2):204-11. doi: 10.1016/j.metabol.2012.07.016. Epub 2012 Sep 15. Metabolism. 2013. PMID: 22985906 Free article. Clinical Trial.
OBJECTIVES: Evidence for a causal relationship between sleep-loss and metabolism is derived primarily from short-term sleep deprivation studies in the laboratory. The objective of this study was to investigate whether small changes in sleep duration over a three week perio …
OBJECTIVES: Evidence for a causal relationship between sleep-loss and metabolism is derived primarily from short-term sleep deprivati …
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators. Heller S, et al. Among authors: russell jones d. Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9. Lancet. 2012. PMID: 22521071 Clinical Trial.
BACKGROUND: Intensive basal-bolus insulin therapy has been shown to improve glycaemic control and reduce the risk of long-term complications that are associated with type 1 diabetes mellitus. ...
BACKGROUND: Intensive basal-bolus insulin therapy has been shown to improve glycaemic control and reduce the risk of long-term compli …
24 results